Ipsen said it will withdraw the EZH2 inhibitor Tazverik from the market after independent monitors identified cases of secondary hematologic malignancies in a confirmatory trial for follicular lymphoma. The company halted ongoing studies, stopped new dosing and moved to ensure affected patients receive standard‑of‑care therapies while continuing long‑term safety monitoring. Tazverik was initially commercialized after accelerated approvals and represented an asset Epizyme developed before being acquired. Ipsen said the withdrawal should have only a minor financial impact on guidance but flagged broader business‑development credibility questions raised by Jefferies analysts given the drug’s underperformance in sales and the safety findings. This safety‑driven removal underscores the regulatory and commercial risk tied to accelerated approvals that rely on confirmatory trials; companies with similar confirmatory obligations will face heightened investor and regulatory scrutiny.